# Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

> **NCT02096861** · PHASE3 · COMPLETED · sponsor: **Celltrion** · enrollment: 220 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** CT-P13
- **BIOLOGICAL:** Remicade

## Key facts

- **NCT ID:** NCT02096861
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-19
- **Primary completion:** 2016-01-11
- **Final completion:** 2017-02-15
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2018-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02096861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02096861, "Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02096861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*